Education
About Us
Working with TipRanks
Follow Us
SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
Top Page
SIGA Technologies
(NASDAQ:SIGA)
76Outperform
SIGA Technologies (SIGA) vs. S&P 500 (SPY)
Market Cap
$391.47M
Dividend Yield10.95%
Average Volume (3M)488.50K
Price to Earnings (P/E)6.7
Beta (1Y)1.02
Revenue Growth-0.86%
EPS Growth-13.33%
CountryUS
Employees46
SectorHealthcare
Sector Strength62
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.83
Shares Outstanding71,436,930
10 Day Avg. Volume377,130
30 Day Avg. Volume488,502
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.89
Price to Cash Flow (P/CF)1.80
P/FCF Ratio1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SIGA Technologies Business Overview & Revenue Model
Company DescriptionSIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
How the Company Makes MoneySIGA Technologies generates revenue primarily through government contracts and sales of its antiviral products. A significant portion of its income is derived from contracts with the U.S. government, particularly through the Biomedical Advanced Research and Development Authority (BARDA) for the procurement of TPOXX to maintain the national stockpile for biodefense. Additionally, SIGA benefits from international government contracts and collaborations with global health organizations seeking to bolster their emergency preparedness. The company may also earn from licensing agreements and future expansion of its product line for commercial markets.
SIGA Technologies Financial Statement Overview
Summary
SIGA Technologies exhibits strong financial health characterized by high profitability, a robust balance sheet with no debt, and sufficient cash flow generation. The company demonstrates excellent cost control and capital management. However, stagnant revenue growth and a decline in operating cash flow are areas to monitor closely for future financial performance.Income Statement
SIGA Technologies has shown strong profitability with consistent gross and net profit margins over the years. The gross profit margin remains high at 100% in the latest year, indicating effective cost management. The net profit margin, although slightly reduced from the previous year, is still robust at 42.7%. However, the revenue growth has been stagnant, with a slight decrease of 0.9% from the prior year, which could suggest a plateau in sales expansion.85
Very Positive
Balance Sheet
The company maintains a solid financial position with no debt, reflected in a debt-to-equity ratio of 0. The equity ratio is strong at 88.3%, indicating financial stability and a low-risk profile. Return on equity (ROE) is healthy at 27.4%, showcasing effective use of equity financing to generate profits. The absence of debt reduces financial risk significantly.88
Very Positive
Cash Flow
Operating cash flow has decreased by 48.6% compared to the previous year, which could be a concern if the trend continues. However, free cash flow remains positive, indicating the company can cover its capital expenditures. The free cash flow to net income ratio is satisfactory, showing that profits are backed by cash generation. The decline in cash flow growth rate is a potential risk area.78
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 138.72M | 139.92M | 110.78M | 133.67M | 124.96M | Gross Profit |
| 138.72M | 122.09M | 77.82M | 107.13M | 99.22M | EBIT |
| 129.49M | 83.62M | 42.70M | 89.09M | 84.50M | EBITDA |
| 70.52M | 84.16M | 43.22M | 89.62M | 85.03M | Net Income Common Stockholders |
| 59.21M | 68.07M | 33.90M | 69.45M | 56.34M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 155.40M | 150.15M | 98.79M | 103.14M | 117.89M | Total Assets |
| 244.34M | 254.35M | 195.04M | 214.73M | 149.83M | Total Debt |
| 546.82K | 564.01K | 528.17K | 466.83K | 449.94K | Net Debt |
| -155.40M | -149.58M | -98.26M | -102.67M | -117.44M | Total Liabilities |
| 28.53M | 57.49M | 24.88M | 40.41M | 20.04M | Stockholders Equity |
| 215.80M | 196.86M | 170.16M | 174.31M | 129.79M |
| Cash Flow | Free Cash Flow | |||
| 48.72M | 94.78M | 41.61M | 11.44M | 71.50M | Operating Cash Flow |
| 48.76M | 94.80M | 41.61M | 11.49M | 71.52M | Investing Cash Flow |
| -42.45K | -21.69K | 0.00 | -50.62K | -15.50K | Financing Cash Flow |
| -43.46M | -43.42M | -45.96M | -26.20M | -114.60M |
SIGA Technologies Technical Analysis
Negative
5.50
Price Trends
5.82
Negative
6.15
Negative
7.11
Negative
Market Momentum
-0.06
Positive
42.96
Neutral
15.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Negative. The current price of 5.5 is below the 20-day moving average (MA) of 5.66, below the 50-day MA of 5.82, and below the 200-day MA of 7.11, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 42.96 is Neutral, neither overbought nor oversold. The STOCH value of 15.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGA.
SIGA Technologies Risk Analysis
SIGA Technologies disclosed 39 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SIGA Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $391.47M | 6.65 | 28.70% | 10.95% | -0.86% | -13.33% | |
58 Neutral | $1.50B | 54.86 | -35.00% | ― | 43.50% | ― | |
50 Neutral | $264.08M | ― | -33.67% | ― | -0.62% | 75.57% | |
49 Neutral | $92.78M | ― | -114.71% | ― | 288.94% | 39.45% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
39 Underperform | $1.03B | ― | 30.06% | ― | -30.65% | 77.62% | |
34 Underperform | $59.77M | ― | -115.42% | ― | -73.83% | 34.81% |
* Healthcare Sector Average
Performance Comparison
SIGA
SIGA Technologies
5.50
-4.41
-44.50%
EBS
Emergent Biosolutions
5.17
2.91
128.76%
INO
Inovio Pharmaceuticals
1.66
-10.68
-86.55%
MNKD
MannKind
5.02
0.59
13.32%
NVAX
Novavax
5.98
1.44
31.72%
VXRT
Vaxart
0.35
-0.88
-71.54%
SIGA Technologies Earnings Call Summary
Earnings Call Date: Mar 11, 2025 | % Change Since: -1.79% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
SIGA had a year of strong financial performance and strategic progress, with notable sales growth and international expansion. Challenges with mpox clinical trials were addressed, but they did not significantly dampen the overall positive trajectory. The company's strong cash position and strategic partnerships provide a solid foundation for future growth.Highlights
Continued Product Sales Growth
2024 product sales reached $133 million, a 2% increase from 2023, marking the second consecutive year of growth.
Significant Fourth Quarter Revenue
$80 million generated in the fourth quarter, driven by diverse revenue sources including the U.S. strategic national stockpile and international markets.
International Expansion Achievements
TPOXX received regulatory approval in Japan, and a notable $11 million sale in East Asia, more than doubling the largest prior sale in the region.
Strong Financial Position
SIGA ended the year with a cash balance of $155 million and no debt, reflecting strong financial discipline.
Strategic Partnerships for Long-term Growth
An exclusive license agreement with Vanderbilt University for monoclonal antibodies with potential to complement the TPOXX franchise.
Lowlights
Challenges with Mpox Clinical Trials
PALM 007 and STOMP trials did not show statistical significance at the primary endpoint, leading to discussions on TPOXX's use for mpox.
Reduced Pretax Operating Income
Pretax operating income for 2024 was $70 million, down from $84 million in 2023, due to different product mixes.
Company Guidance
During the SIGA business update call for the fiscal year 2024, CEO Diem Nguyen highlighted a year of strong financial performance with product sales reaching $133 million, marking a 2% increase from 2023. The fourth quarter alone contributed $80 million to these sales, predominantly from deliveries of oral and IV TPOXX to the U.S. strategic national stockpile and the Department of Defense, as well as an $11 million sale in East Asia. The company reported a pretax operating income of $57 million for the fourth quarter and $70 million for the full year, with net income at $46 million and $59 million, respectively. The diluted earnings per share were $0.63 for the fourth quarter and $0.82 for the full year. SIGA maintained a robust cash position with $155 million in cash and no debt at year-end, and a $70 million outstanding order balance expected to be delivered in 2025. The company also advanced its international presence with a regulatory approval in Japan and assumed responsibility for promoting TPOXX outside the U.S., while continuing to explore strategic partnerships and pipeline diversification, including a collaboration on monoclonal antibodies with Vanderbilt University.SIGA Technologies Corporate Events
Executive/Board Changes
SIGA Technologies Appoints Gen. Keane as New Director
Positive
Mar 18, 2025
On March 17, 2025, SIGA Technologies appointed General John M. ‘Jack’ Keane (Ret.) as a director, effective immediately. Gen. Keane received stock options and an annual retainer, with his appointment aligning with Nasdaq’s independence requirements, potentially strengthening the company’s governance and strategic direction.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.